

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/017,905	ATTY. DOCKET NO.: B0801.70238US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 14, 2001	CONFIRMATION NO.: 7653
				APPLICANT: Paul Ridker et al.	
Sheet	I	of	1	GROUP ART UNIT: 1644	EXAMINER: G. R. Ewoldt

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Crestor (rosuvastatin calcium) tablets. FDA label and approval information. Drugs@FDA.gov. Supplement Number 16. Last approved February 8, 2010. 43 pages.	

EXAMINER: _____ DATE CONSIDERED: _____

⁴ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, pending U.S. patent applications, or pending, unpublished patent applications stored in the USPTO’s Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]